Compare CMCL & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMCL | CHRS |
|---|---|---|
| Founded | 1992 | 2010 |
| Country | Jersey | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 396.3M | 209.8M |
| IPO Year | 2003 | 2014 |
| Metric | CMCL | CHRS |
|---|---|---|
| Price | $19.38 | $1.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $28.00 | $5.51 |
| AVG Volume (30 Days) | 243.8K | ★ 950.1K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $38.54 | $73.08 |
| Revenue Next Year | N/A | $30.94 |
| P/E Ratio | $10.88 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.45 | $0.73 |
| 52 Week High | $38.75 | $2.62 |
| Indicator | CMCL | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 39.44 | 46.49 |
| Support Level | $18.45 | $1.37 |
| Resistance Level | $21.80 | $1.79 |
| Average True Range (ATR) | 0.80 | 0.08 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 23.74 | 53.19 |
Caledonia Mining Corp PLC is a gold exploration, development, and mining company. The company's segment includes Blanket, South Africa, Bilboes Oxide mine, and E&E projects. The company generates the majority of its revenue from the Blanket project. The Blanket Mine is located in the south-west of Zimbabwe and operates at a depth of approximately 750 meters below the surface. Its project includes Maligreen and Motapa.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.